Nature's Sunshine (NATR) Q3 2026 Earnings Call Transcript
Nature's Sunshine (NATR) reported Q3 2026 net sales of $116.6M, down 7% YoY (9% including FX). Declines were driven by China (-52%) and slower digital growth in North America. The company lowered its full-year outlook to $460M-$470M in sales and $44M-$48M in adjusted EBITDA, citing continued challenges in Asia and digital normalization.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance cut are likely to drive short‑term downside, but the company retains cash and no debt.
Market read
The earnings release provides fresh material for traders; the guidance downgrade is the primary catalyst.
What to watch
Strong autoship growth in digital sales and a cash‑rich balance sheet could support a rebound.
Background
Nature's Sunshine (NATR) reported Q3 2026 results, highlighting a 9% YoY sales decline and a lowered FY2026 outlook.
Ticker impact
Q3 2026 earnings release with net sales down 9% YoY and lowered full-year outlook to $460‑$470M.
downward pressure as market prices in lower revenue and EBITDA guidance
Earnings miss and reduced outlook are fresh primary disclosures that typically trigger sell‑offs.
Market effects
Direct‑selling and health‑supplement sector may see broader weakness due to China slowdown.
Asian markets, especially China and Taiwan, could face additional pressure from the sales decline.
Limited to investors in small‑cap consumer health stocks; unlikely to affect broader indices.
Counterpoint
If the company can successfully rebuild its consultant base in China, the stock may be oversold.
Key entities
- companyNature's Sunshine
US‑listed direct‑selling health‑supplement firm (ticker NATR).
